Information Provided By:
Fly News Breaks for June 9, 2017
ENDP, COLL
Jun 9, 2017 | 09:13 EDT
William Blair analyst Tim Lugo views FDA request to remove Endo's (ENDP) Opana ER from the market as a positive for Collegium Pharmaceutical (COLL). The analyst believes Collegium's Xtampza ER has a "best-in-class abuse-deterrent profile." He thinks the drug's scripts could "meaningfully ramp up in the near term." Lugo keeps an Outperform rating on Collegium.
News For COLL;ENDP From the Last 2 Days
There are no results for your query COLL;ENDP